Do Not Treat Asymptomatic VRE Bacteriuria
You should NOT treat this patient. A urine culture showing 20,000-25,000 CFU/mL of VRE without urinary tract infection symptoms represents asymptomatic bacteriuria (ASB) or colonization, and antimicrobial therapy is not indicated.
Why Treatment is Not Recommended
The 2019 IDSA guidelines for asymptomatic bacteriuria explicitly recommend against screening for or treating ASB in patients with long-term indwelling catheters (strong recommendation) 1. This principle extends to patients without catheters who have bacteriuria without symptoms.
The critical distinction here is between colonization/ASB versus true infection:
- Colony count is irrelevant for treatment decisions - the presence or absence of UTI symptoms determines management, not the CFU/mL
- Studies show that 60-92% of patients with VRE isolated from urine cultures have colonization or ASB, not true infection 2
- In one retrospective study of 98 patients with VRE bacteriuria, only 13 (13%) had true UTI, while 37 had colonization and 21 had asymptomatic bacteriuria 2
When VRE Bacteriuria DOES Require Treatment
Treatment is indicated only when the patient has documented UTI symptoms, which include:
- Lower UTI (cystitis): Dysuria, urgency, frequency, suprapubic pain
- Upper UTI (pyelonephritis): Fever, flank pain, costovertebral angle tenderness
- Systemic signs: Bacteremia, sepsis
Treatment Options IF Symptoms Were Present
If this patient develops UTI symptoms, the 2022 guidelines provide clear treatment recommendations for uncomplicated VRE UTI 3:
First-line oral options:
- Fosfomycin 3 g PO single dose (weak recommendation, very low quality evidence)
- Nitrofurantoin 100 mg PO every 6 hours (weak recommendation, very low quality evidence)
- High-dose ampicillin (18-30 g IV daily in divided doses) or amoxicillin 500 mg PO/IV every 8 hours - if ampicillin-susceptible (weak recommendation, very low quality evidence)
For complicated/upper tract VRE UTI:
- Linezolid 600 mg IV or PO every 12 hours (strong recommendation, low quality evidence) 3
- High-dose daptomycin 8-12 mg/kg IV daily - reserved for bacteremic UTI (weak recommendation, low quality evidence) 3
Important Clinical Pearls
Ampicillin susceptibility matters: Despite vancomycin resistance, 82% of VRE E. faecalis isolates remain ampicillin-susceptible 4. High urinary concentrations of ampicillin can overcome resistance and achieve bactericidal activity in the urinary tract 3.
Avoid unnecessary broad-spectrum agents: Studies show daptomycin and linezolid are frequently overused for VRE bacteriuria when ampicillin or oral agents would suffice 4. This contributes to antimicrobial resistance and unnecessary toxicity.
Linezolid has limited urinary excretion but clinical data suggest it is effective for mild-to-moderate VRE UTI 5. However, it should be reserved for true infections, not colonization.
Common pitfall: The most frequent error is treating asymptomatic bacteriuria. The 2019 IDSA guidelines emphasize that "it is important to differentiate colonization from true infection prior to empiric prescription of anti-VRE antimicrobial agents" 3.
Bottom Line
With a colony count of 20,000-25,000 CFU/mL VRE and no symptoms, this represents colonization or asymptomatic bacteriuria. No treatment is indicated. Unnecessary antibiotic use promotes resistance, exposes the patient to drug toxicity, and provides no clinical benefit. Only treat if clear UTI symptoms develop, then use targeted therapy based on susceptibility testing and infection severity.